TerrAscend To Host First Quarter 2020 Investor Conference Call

INNO

NEW YORK and TORONTOMay 21, 2020 // – TerrAscend Corp. (“TerrAscend”) (CSE:TER, OTCQX: TRSSF), a leading North American cannabis operator, today announced a scheduled conference call to discuss the results for its first quarter ended March 31, 2020 on Friday, May 29th, 2020 at 8:30 a.m. Eastern Time. The Company will report its financial results for the first quarter after the close of markets on Thursday, May 28th, 2020.

CONFERENCE CALL DETAILS
DATE:Friday, May 29th, 2020
TIME:8:30 a.m. Eastern Time
WEBCAST:Click to Access
DIAL-IN NUMBER:1 (888) 664-6392
CONFERENCE ID:62330066
REPLAY:(416) 764-8677 or (888) 390-0541
Available until 12:00 midnight Eastern Time Friday, June 12th, 2020

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, TerrAscend participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend was the first cannabis company with sales in the US, Canada, and Europe. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with several retail locations in California; Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. TerrAscend holds a cultivation permit in the State of New Jersey and is pending approval for a vertically integrated medical cannabis operation with the ability to operate up to 3 Alternative Treatment Centers. Additionally, TerrAscend holds a Medical Cannabis Processor License in the State of Utah. For more information, visit http://www.terrascend.com.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

For more information regarding TerrAscend: 

Keith Stauffer
Chief Financial Officer
IR@terrascend.com

Rob Kelly
Investor Relations, Mattio Communications
TerrAscend@mattio.com
1-416-992-4539

SOURCE TERRASCEND

 

All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. Candlr is not receiving payment or commissions from companies for shared content on Candlr website unless its specified. View full disclaimer HERE.

Forums Topics

Viewing 15 topics - 1 through 15 (of 66 total)
Viewing 15 topics - 1 through 15 (of 66 total)

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.